|
1
|
Bosman FT: World Health Organization and
International Agency for Research on Cancer: WHO classification of
tumours of the digestive system. 4th. IARC Press; Lyon: 2010
|
|
2
|
Sia D, Villanueva A, Friedman SL and
Llovet JM: Liver cancer cell of origin, molecular class, and
effects on patient prognosis. Gastroenterology. 152:745–761. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bosch FX, Ribes J, Diaz M and Cleries R:
Primary liver cancer: Worldwide incidence and trends.
Gastroenterology. 127 5 Suppl 1:S5–S16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Dageforde LA, Fowler KJ and Chapman WC:
Liver transplantation for hepatocellular carcinoma: Current update
on treatment and allocation. Curr Opin Organ Transplant.
22:128–134. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fitamant J, Kottakis F, Benhamouche S,
Tian HS, Chuvin N, Parachoniak CA, Nagle JM, Perera RM, Lapouge M,
Deshpande V, et al: YAP inhibition restores hepatocyte
differentiation in advanced HCC, leading to tumor regression. Cell
Rep. Mar 10–2015.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tsurusaki M and Murakami T: Surgical and
locoregional therapy of HCC: TACE. Liver Cancer. 4:165–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sun JJ, Wang K, Zhang CZ, Guo WX, Shi J,
Cong WM, Wu MC, Lau WY and Cheng SQ: Postoperative adjuvant
transcatheter arterial chemoembolization after R0 hepatectomy
improves outcomes of patients who have hepatocellular carcinoma
with microvascular invasion. Ann Surg Oncol. 23:1344–1351. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirakawa M, Nishie A, Asayama Y, Fujita N,
Ishigami K, Tajiri T, Taguchi T and Honda H: Efficacy of
preoperative transcatheter arterial chemoembolization combined with
systemic chemotherapy for treatment of unresectable hepatoblastoma
in children. Jpn J Radiol. 32:529–536. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu K, Min XL, Peng J, Yang K, Yang L and
Zhang XM: The changes of HIF-1α and VEGF expression after TACE in
patients with hepatocellular carcinoma. J Clin Med Res. 8:297–302.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jiao D, Wang J, Lu W, Tang X, Chen J, Mou
H and Chen QY: Curcumin inhibited HGF-induced EMT and angiogenesis
through regulating c-Met dependent PI3K/Akt/mTOR signaling pathways
in lung cancer. Mol Ther Oncolytics. 3:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Abdollahi E, Momtazi AA, Johnston TP and
Sahebkar A: Therapeutic effects of curcumin in inflammatory and
immune-mediated diseases: A nature-made jack-of-all-trades? J Cell
Physiol. 233:830–848. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang J, Xu L, Zhang L, Ying Z, Su W and
Wang T: Curcumin attenuates
D-galactosamine/lipopolysaccharide-induced liver injury and
mitochondrial dysfunction in mice. J Nutr. 144:1211–1218. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Salem MM, El-Rasheid HGA and Mahmoud AN:
Therapeutic effects of curcumin and royal jelly as natural
antioxidants on some biochemical parameters in hepatotoxicity
induced by carbon tetrachloride (CCl4) in male albino rats. Int J.
3:520–535. 2015.
|
|
14
|
Li G, Chen JB, Wang C, Xu Z, Nie H, Qin
XY, Chen XM and Gong Q: Curcumin protects against
acetaminophen-induced apoptosis in hepatic injury. World J
Gastroenterol. 19:7440–7446. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Mitsiades CS, Mitsiades NS, McMullan CJ,
Poulaki V, Shringarpure R, Akiyama M, Hideshima T, Chauhan D,
Joseph M, Libermann TA, et al: Inhibition of the insulin-like
growth factor receptor-1 tyrosine kinase activity as a therapeutic
strategy for multiple myeloma, other hematologic malignancies, and
solid tumors. Cancer Cell. 5:221–230. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Patel BB, Gupta D, Elliott AA, Sengupta V,
Yu Y and Majumdar AP: Curcumin targets FOLFOX-surviving colon
cancer cells via inhibition of EGFRs and IGF-1R. Anticancer Res.
30:319–325. 2010.PubMed/NCBI
|
|
17
|
Samani AA, Yakar S, LeRoith D and Brodt P:
The role of the IGF system in cancer growth and metastasis:
Overview and recent insights. Endocr Rev. 28:20–47. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
El-Serag HB, Davila JA, Petersen NJ and
McGlynn KA: The continuing increase in the incidence of
hepatocellular carcinoma in the United States: An update. Ann
Intern Med. 139:817–823. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liao D and Johnson RS: Hypoxia: A key
regulator of angiogenesis in cancer. Cancer Metastasis Rev.
26:281–290. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nishida N, Yano H, Nishida T, Kamura T and
Kojiro M: Angiogenesis in cancer. Vasc Health Risk Manag.
2:213–219. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Pleguezuelo M, Marelli L, Misseri M,
Germani G, Calvaruso V, Xiruochakis E, Manousou P and Burroughs AK:
TACE versus TAE as therapy for hepatocellular carcinoma. Expert Rev
Anticancer Ther. 8:1623–1641. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Poon RT, Ho JW, Tong CS, Lau C, Ng IO and
Fan ST: Prognostic significance of serum vascular endothelial
growth factor and endostatin in patients with hepatocellular
carcinoma. Br J Surg. 91:1354–1360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Park YN, Kim YB, Yang KM and Park C:
Increased expression of vascular endothelial growth factor and
angiogenesis in the early stage of multistep hepatocarcinogenesis.
Arch Pathol Lab Med. 124:1061–1065. 2000.PubMed/NCBI
|
|
24
|
Yamaguchi R, Yano H, Iemura A, Ogasawara
S, Haramaki M and Kojiro M: Expression of vascular endothelial
growth factor in human hepatocellular carcinoma. Hepatology.
28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sergio A, Cristofori C, Cardin R, Pivetta
G, Ragazzi R, Baldan A, Girardi L, Cillo U, Burra P, Giacomin A and
Farinati F: Transcatheter arterial chemoembolization (TACE) in
hepatocellular carcinoma (HCC): The role of angiogenesis and
invasiveness. Am J Gastroenterol. 103:914–921. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liapi E and Geschwind JF: Combination of
local transcatheter arterial chemoembolization and systemic
anti-angiogenic therapy for unresectable hepatocellular carcinoma.
Liver Cancer. 1:201–215. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Hu P, Chen X and Bie P:
Transarterial chemoembolization (TACE) plus sorafenib versus TACE
for intermediate or advanced stage hepatocellular carcinoma: A
meta-analysis. PLoS One. 9:e1003052014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu M, Zheng YL, Xie XY, Liang JY, Pan FS,
Zheng SG and Lü MD: Sorafenib blocks the HIF-1α/VEGFA pathway,
inhibits tumor invasion, and induces apoptosis in hepatoma cells.
DNA Cell Biol. 33:275–281. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Liu L, Chen H, Wang M, Zhao Y, Cai G, Qi X
and Han G: Combination therapy of sorafenib and TACE for
unresectable HCC: A systematic review and meta-analysis. PLoS One.
9:e911242014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shehzad A, Lee J and Lee YS: Curcumin in
various cancers. Biofactors. 39:56–68. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
North S, Moenner M and Bikfalvi A: Recent
developments in the regulation of the angiogenic switch by cellular
stress factors in tumors. Cancer Lett. 218:1–14. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Q, Xu Z, Mao S, Chen W, Zeng R, Zhou S
and Liu J: Effect of hypoxia on hypoxia inducible factor-1α,
insulin-like growth factor I and vascular endothelial growth factor
expression in hepatocellular carcinoma HepG2 cells. Oncol Lett.
9:1142–1148. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Gray SG, Eriksson T, Ekström C, Holm S,
von Schweinitz D, Kogner P, Sandstedt B, Pietsch T and Ekström TJ:
Altered expression of members of the IGF-axis in hepatoblastomas.
Br J Cancer. 82:1561–1567. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Tomizawa M and Saisho H: Signaling pathway
of insulin-like growth factor-II as a target of molecular therapy
for hepatoblastoma. World J Gastroenterol. 12:6531–6535. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yue L, Wang Y, Wang H, Gao H, Liang J, Sui
A, Xiang J, Zhou F, Xu C, Zhao W, et al: Inhibition of
hepatocellular carcinoma cell growth by an anti-insulin-like growth
factor-I receptor monoclonal antibody. Oncol Rep. 28:1453–1460.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rey S and Semenza GL: Hypoxia-inducible
factor-1-dependent mechanisms of vascularization and vascular
remodelling. Cardiovasc Res. 86:236–242. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Simpson A, Petnga W, Macaulay VM,
Weyer-Czernilofsky U and Bogenrieder T: Insulin-like growth factor
(IGF) pathway targeting in cancer: Role of the IGF Axis and
opportunities for future combination studies. Target Oncol.
12:571–597. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Arany Z, Foo SY, Ma Y, Ruas JL,
Bommi-Reddy A, Girnun G, Cooper M, Laznik D, Chinsomboon J,
Rangwala SM, et al: HIF-independent regulation of VEGF and
angiogenesis by the transcriptional coactivator PGC-1alpha. Nature.
451:1008–1012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
López-Terrada D, Cheung SW, Finegold MJ
and Knowles BB: Hep G2 is a hepatoblastoma-derived cell line. Hum
Pathol. 40:1512–1515. 2009. View Article : Google Scholar
|
|
40
|
Shoji M, Nakagawa K, Watanabe A, Tsuduki
T, Yamada T, Kuwahara S, Kimura F and Miyazawa T: Comparison of the
effects of curcumin and curcumin glucuronide in human
hepatocellular carcinoma HepG2 cells. Food Chem. 151:126–132. 2014.
View Article : Google Scholar : PubMed/NCBI
|
